...
首页> 外文期刊>Cancer Cell >Cholesterol Pathway Inhibition Induces TGF-beta Signaling to Promote Basal Differentiation in Pancreatic Cancer
【24h】

Cholesterol Pathway Inhibition Induces TGF-beta Signaling to Promote Basal Differentiation in Pancreatic Cancer

机译:胆固醇途径抑制诱导TGF-Beta信号传导,促进胰腺癌中的基础分化

获取原文
获取原文并翻译 | 示例
           

摘要

Oncogenic transformation alters lipid metabolism to sustain tumor growth. We define a mechanism by which cholesterol metabolism controls the development and differentiation of pancreatic ductal adenocarcinoma (PDAC). Disruption of distal cholesterol biosynthesis by conditional inactivation of the rate-limiting enzyme Nsdhl or treatment with cholesterol-lowering statins switches glandular pancreatic carcinomas to a basal (mesenchymal) phenotype in mouse models driven by Kras(G12D) expression and homozygous Trp53 loss. Consistently, PDACs in patients receiving statins show enhanced mesenchymal features, Mechanistically, statins and NSDHL loss induce SREBP1 activation, which promotes the expression of Tgfb1, enabling epithelial-mesenchymal transition. Evidence from patient samples in this study suggests that activation of transforming growth factor beta signaling and epithelial-mesenchymal transition by cholesterol-lowering statins may promote the basal type of PDAC, conferring poor outcomes in patients.
机译:致癌转化改变脂质代谢以维持肿瘤生长。我们定义了胆固醇代谢控制胰腺导管腺癌(PDAC)发展和分化的机制。在Kras(G12D)表达和纯合Trp53缺失驱动的小鼠模型中,通过条件失活限速酶Nsdhl或使用降胆固醇他汀类药物治疗破坏远端胆固醇生物合成,将腺性胰腺癌转变为基础(间充质)表型。一直以来,接受他汀类药物治疗的患者的PDAC表现出增强的间充质特征,从机制上讲,他汀类药物和NSDHL缺失诱导SREBP1激活,从而促进Tgfb1的表达,实现上皮-间充质转化。本研究中来自患者样本的证据表明,通过降胆固醇他汀类药物激活转化生长因子β信号传导和上皮-间质转化,可能会促进PDAC的基础类型,导致患者预后不佳。

著录项

  • 来源
    《Cancer Cell》 |2020年第4期|共28页
  • 作者单位

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Biostat &

    Bioinformat Facil 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Marvin &

    Concetta Greenberg Pancreat Canc Inst 7701 Burholme Ave Philadelphia;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Wistar Inst Anat &

    Biol Prote &

    Metabol Facil 3601 Spruce St Philadelphia PA 19104 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Marvin &

    Concetta Greenberg Pancreat Canc Inst 7701 Burholme Ave Philadelphia;

    Fox Chase Canc Ctr Canc Biol Program 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Marvin &

    Concetta Greenberg Pancreat Canc Inst 7701 Burholme Ave Philadelphia;

    Fox Chase Canc Ctr Biostat &

    Bioinformat Facil 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Canc Biol Program 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Champ Oncol Inc Hackensack NJ USA;

    Champ Oncol Inc Hackensack NJ USA;

    Stony Brook Canc Ctr Dept Biomed Informat Stony Brook NY USA;

    NexusPharma Inc Philadelphia PA USA;

    Fox Chase Canc Ctr Canc Prevent &

    Control Program 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Marvin &

    Concetta Greenberg Pancreat Canc Inst 7701 Burholme Ave Philadelphia;

    Fox Chase Canc Ctr Mol Therapeut Program 333 Cottman Ave Philadelphia PA 19111 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号